MYC expression correlates with PD-L1 expression in non-small cell lung cancer - PubMed (original) (raw)
MYC expression correlates with PD-L1 expression in non-small cell lung cancer
Eun Young Kim et al. Lung Cancer. 2017 Aug.
Abstract
Objectives Programmed death-ligand 1 (PD-L1) is a widely used biomarker for predicting immune checkpoint inhibitors, but is of limited usefulness in the prediction of drug response. MYC, a transcription factor that is overexpressed in cancers, is involved in preventing immune cells from attacking tumor cells through inducing PD-L1 expression. This study evaluated the relationship between MYC and PD-L1 expression in 84 non-small cell lung cancer (NSCLC) patients who underwent curative surgical resection. Materials and Methods The relationship between MYC and PD-L1 was investigated by introducing pcDNA3-cMYC into A549 and H1299 cells with low PD-L1 expression and siRNA against MYC into H60 and H2009 cells with high PD-L1 expression. Expression of PD-L1 in NSCLC tissues was analyzed by immunostaining using a PD-L1 (22C3) PharmDx protocol using the Dako Automated Link 48 platform and expression of MYC was determined using anti-c-MYC (Y69) (ab320720). Results Of 84 patients, PD-L1 was expressed in 14 (16.7%) and MYC was overexpressed in 30 (35.7%). We investigated the relationship between PD-L1 and MYC expression. There were 49 (58.3%) double-negative patients and 9 (10.7%) double-positive patients. Significant positive correlation was observed between PD-L1 and MYC expression (γ=0.210, P=0.029). Double-negative patients showed better disease free (31.1 vs. 7.1 months, P=0.011) and overall survival (56.1 vs. 14.4 months, P=0.032) than double-positive patients. Conclusion Taken together, MYC expression significantly correlated with PD-L1 expression in NSCLC. The usefulness of MYC expression as a surrogate marker of treatment response assessment is worth evaluating for immune checkpoint inhibitor therapy and special interest are required for the subgroup of NSCLC patients, whose tumor expresses PD-L1 and MYC double positive.
Keywords: Immune checkpoint inhibitors; Myc; Non-small cell lung cancer (NSCLC); PD-L1.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
- Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
Büttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, Dietel M, Longshore JW, López-Ríos F, Penault-Llorca F, Viale G, Wotherspoon AC, Kerr KM, Tsao MS. Büttner R, et al. J Clin Oncol. 2017 Dec 1;35(34):3867-3876. doi: 10.1200/JCO.2017.74.7642. Epub 2017 Oct 20. J Clin Oncol. 2017. PMID: 29053400 Review. - PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, Midha A, Walker J. Brody R, et al. Lung Cancer. 2017 Oct;112:200-215. doi: 10.1016/j.lungcan.2017.08.005. Epub 2017 Aug 10. Lung Cancer. 2017. PMID: 29191596 Review. - Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer® Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer.
Erber R, Stöhr R, Herlein S, Giedl C, Rieker RJ, Fuchs F, Ficker JH, Hartmann A, Veltrup E, Wirtz RM, Brueckl WM. Erber R, et al. Anticancer Res. 2017 Dec;37(12):6771-6778. doi: 10.21873/anticanres.12137. Anticancer Res. 2017. PMID: 29187455 - The Prognostic Value of Measuring PD-L1 mRNA Expression Levels in Surgically Resected Non-Small Cell Lung Cancer.
Kim GJ, Lee JH, Park WJ, Lee HW, Hwang IS, Lee DH. Kim GJ, et al. Ann Clin Lab Sci. 2019 May;49(3):317-323. Ann Clin Lab Sci. 2019. PMID: 31308030 - PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.
He Y, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Yu H, Zhou C, Hirsch FR. He Y, et al. Med Sci Monit. 2017 Mar 9;23:1208-1216. doi: 10.12659/msm.899909. Med Sci Monit. 2017. PMID: 28275222 Free PMC article.
Cited by
- Tumor immune checkpoints and their associated inhibitors.
Gao Z, Ling X, Shi C, Wang Y, Lin A. Gao Z, et al. J Zhejiang Univ Sci B. 2022 Oct 15;23(10):823-843. doi: 10.1631/jzus.B2200195. J Zhejiang Univ Sci B. 2022. PMID: 36226537 Free PMC article. Review. - From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer.
Zhou Y, Wang F, Li G, Xu J, Zhang J, Gullen E, Yang J, Wang J. Zhou Y, et al. Front Immunol. 2024 Feb 15;15:1340307. doi: 10.3389/fimmu.2024.1340307. eCollection 2024. Front Immunol. 2024. PMID: 38426097 Free PMC article. Review. - Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma.
Xu Y, Hao X, Ren Y, Xu Q, Liu X, Song S, Wang Y. Xu Y, et al. Front Oncol. 2023 Jan 6;12:1063423. doi: 10.3389/fonc.2022.1063423. eCollection 2022. Front Oncol. 2023. PMID: 36686771 Free PMC article. Review. - From Super-Enhancer Non-coding RNA to Immune Checkpoint: Frameworks to Functions.
Wu M, Shen J. Wu M, et al. Front Oncol. 2019 Nov 22;9:1307. doi: 10.3389/fonc.2019.01307. eCollection 2019. Front Oncol. 2019. PMID: 31824865 Free PMC article. Review. - MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products.
Chan KI, Zhang S, Li G, Xu Y, Cui L, Wang Y, Su H, Tan W, Zhong Z. Chan KI, et al. Aging Dis. 2024 Apr 1;15(2):640-697. doi: 10.14336/AD.2023.0520. Aging Dis. 2024. PMID: 37450923 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials